SCHEDULE: TuHURA Biosciences: CEO's Stake Drops Below 5%

James A. Bianco, M.D., CEO of TuHURA Biosciences, Inc., has filed an amendment to reduce his beneficial ownership below 5% due to share dilution from a fee arrangement, marking an exit filing.

Summary

• James A. Bianco, M.D., President, CEO, and director of TuHURA Biosciences, Inc., has filed an amendment to Schedule 13D.
• This filing indicates that his beneficial ownership of the company's common stock has fallen below the 5% threshold.
• The reduction is attributed to the issuance of 1,878,287 shares of common stock to Parkview Holdings One LLC, not due to any transaction by Dr. Bianco.
• As of August 18, 2026, Dr. Bianco beneficially owns 3,085,519 shares, representing approximately 4.6% of the outstanding common stock.
• This filing is considered the final amendment to the Original Schedule 13D, marking an 'exit filing' for Dr. Bianco's reporting obligations under Section 13(d).
• Dr. Bianco continues to serve as President, CEO, and a director of the Issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing, primarily due to the reduction in beneficial ownership below a key threshold, signaling a potential shift in the reporting person's stake, though it is framed as an 'exit filing'.

Positives

• Dr. Bianco continues in his executive and director roles, indicating ongoing commitment to the company's management.
• The filing is an 'exit filing', suggesting a potential normalization of reporting requirements for Dr. Bianco.

Negatives

• Beneficial ownership has decreased below the significant 5% threshold, which could be perceived negatively by the market.
• The dilution occurred due to a fee arrangement with Parkview Holdings One LLC, the terms of which are not detailed in this filing.

Risks

• Potential market perception of reduced insider stake below a key reporting threshold.
• The underlying reasons for the fee arrangement with Parkview Holdings One LLC and its long-term implications are not fully disclosed in this amendment.

Future Outlook

The filing does not contain specific forward-looking statements or guidance. However, the 'exit filing' status suggests a potential shift in the reporting person's formal disclosure obligations.

Management Comments

• This Amendment does not reflect or report any transactions in the Issuer's Common Stock by the Reporting Person and is being filed solely to report the reduction in the Reporting Person's beneficial ownership percentage as a result of the Issuer's issuance of shares of Common Stock to a party that is not an affiliate of the Reporting Person.
• The filing of this Amendment represents the final amendment to the Original Schedule 13D and constitutes an exit filing for the Reporting Person.
• The Reporting Person continues to serve as the President and Chief Executive Officer and a director of the Issuer.

Industry Context

StockSavvy.ai notes that a reduction in beneficial ownership below the 5% threshold, especially by a CEO, can sometimes be interpreted as a signal of reduced conviction or a strategic shift, although in this case, it's explicitly attributed to dilution from a third-party transaction rather than a sale by the CEO.

Stakeholder Impact

• Shareholders: May perceive the reduction in the CEO's direct ownership stake below 5% as a negative signal, despite the explanation of dilution.
• Employees: Continued leadership by Dr. Bianco provides stability, but market perception could indirectly affect morale.
• Creditors/Suppliers: No direct impact indicated, as the change is in beneficial ownership percentage, not a sale of shares by management.

Next Steps

• The Reporting Person's reporting obligations under Section 13(d) of the Act with respect to the Common Stock are terminated.
• Dr. Bianco will continue to serve as President and Chief Executive Officer and a director of the Issuer.

Key Dates

Keywords

TuHURA Biosciences, Schedule 13D, Beneficial Ownership, Insider Stake, Dilution, CEO, Director, Exit Filing